BeiGene, Ltd. (688235.SS)
CNY 261.18
(5.78%)
CNY 261.18
(5.78%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.45 Billion USD | 73.65% |
| 2022 | 1.41 Billion USD | 20.37% |
| 2021 | 1.17 Billion USD | 280.83% |
| 2020 | 308.87 Million USD | -27.87% |
| 2019 | 428.21 Million USD | 116.03% |
| 2018 | 198.22 Million USD | -16.85% |
| 2017 | 238.38 Million USD | 22179.16% |
| 2016 | 1.07 Million USD | -87.86% |
| 2015 | 8.81 Million USD | -32.37% |
| 2014 | 13.03 Million USD | 16.93% |
| 2013 | 11.14 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 751.65 Million USD | 18.48% |
| 2024 Q2 | 929.16 Million USD | 23.62% |
| 2023 Q1 | 447.8 Million USD | 17.81% |
| 2023 FY | 2.45 Billion USD | 73.65% |
| 2023 Q4 | 634.4 Million USD | -18.8% |
| 2023 Q3 | 781.3 Million USD | 31.25% |
| 2023 Q2 | 595.26 Million USD | 32.93% |
| 2022 Q3 | 387.62 Million USD | 13.48% |
| 2022 Q2 | 341.57 Million USD | 11.4% |
| 2022 FY | 1.41 Billion USD | 20.37% |
| 2022 Q1 | 306.62 Million USD | 43.3% |
| 2022 Q4 | 380.09 Million USD | -1.94% |
| 2021 Q4 | 213.97 Million USD | 3.65% |
| 2021 Q3 | 206.44 Million USD | 37.63% |
| 2021 FY | 1.17 Billion USD | 280.83% |
| 2021 Q1 | 605.87 Million USD | 505.27% |
| 2021 Q2 | 149.99 Million USD | -75.24% |
| 2020 Q1 | 52.05 Million USD | -8.5% |
| 2020 FY | 308.87 Million USD | -27.87% |
| 2020 Q2 | 65.63 Million USD | 26.08% |
| 2020 Q4 | 100.1 Million USD | 9.9% |
| 2020 Q3 | 91.08 Million USD | 38.77% |
| 2019 FY | 428.21 Million USD | 116.03% |
| 2019 Q4 | 56.89 Million USD | 13.46% |
| 2019 Q2 | 243.34 Million USD | 212.65% |
| 2019 Q1 | 77.83 Million USD | 32.66% |
| 2019 Q3 | 50.14 Million USD | -79.4% |
| 2018 Q4 | 58.67 Million USD | 8.24% |
| 2018 FY | 198.22 Million USD | -16.85% |
| 2018 Q2 | 52.8 Million USD | 62.25% |
| 2018 Q1 | 32.54 Million USD | 79.07% |
| 2018 Q3 | 54.2 Million USD | 2.65% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | 238.38 Million USD | 22179.16% |
| 2017 Q4 | 18.17 Million USD | -91.75% |
| 2017 Q3 | 220.21 Million USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | 677 Thousand USD | -85.52% |
| 2016 Q3 | - USD | -100.0% |
| 2016 FY | 1.07 Million USD | -87.86% |
| 2016 Q2 | 393 Thousand USD | -41.95% |
| 2015 FY | 8.81 Million USD | -32.37% |
| 2015 Q1 | 1.37 Million USD | -0.14% |
| 2015 Q4 | 4.67 Million USD | 238.91% |
| 2015 Q3 | 1.38 Million USD | 0.0% |
| 2015 Q2 | 1.38 Million USD | 0.07% |
| 2014 Q2 | 2.57 Million USD | 0.0% |
| 2014 Q1 | 2.57 Million USD | 0.0% |
| 2014 Q4 | 1.38 Million USD | -78.74% |
| 2014 FY | 13.03 Million USD | 16.93% |
| 2014 Q3 | 6.49 Million USD | 151.88% |
| 2013 FY | 11.14 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Shanghai No.1 Pharmacy Co., Ltd. | 1.81 Billion CNY | -35.134% |
| Jointown Pharmaceutical Group Co., Ltd | 149.7 Billion CNY | 98.358% |
| LBX Pharmacy Chain Joint Stock Company | 22.35 Billion CNY | 89.003% |
| Yifeng Pharmacy Chain Co., Ltd. | 22.58 Billion CNY | 89.115% |
| Yunnan Jianzhijia Health-Chain Co., Ltd. | 9.08 Billion CNY | 72.923% |